Panpan Zhang, Yakun Wang, Jie Li, Lin Shen, Ming Lu. "Updated results from a multicenter, single-arm phase II study of surufatinib plus sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e16342